Osocimab |
| カタログ番号GC72438 |
Osocimab (bay 1213790),抗fxia抗体(ki =2.4 nm;EC50 = 0.2 nM)。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2056878-75-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Osocimab (1.4 nM-1 μM; 30 min) inhibits thrombin generation, and also inhibits FXIa-mediated activation of FIX (FIX conversion) (IC50=16 nM) and FXIa mediated substrate cleavage (IC50=1.2 nM) in human plasma[1].
Osocimab (22.05 mg/mL) inhibits intrinsic pathway-mediated activation of the coagulation cascade[1].
References:
[1]. Schaefer M, et al. Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XI. J Mol Biol. 2019 Dec 6;431(24):4817-4833.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *